Log in

NASDAQ:SLDB - Solid Biosciences Stock Price, Forecast & News

$4.11
-0.15 (-3.52 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$4.08
Now: $4.11
$4.44
50-Day Range
$3.00
MA: $6.70
$12.40
52-Week Range
$2.75
Now: $4.11
$32.85
Volume599,399 shs
Average Volume1.03 million shs
Market Capitalization$189.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLDB
CUSIPN/A
Phone617-337-4680

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.53 per share

Profitability

Net Income$-74,800,000.00

Miscellaneous

Employees111
Market Cap$189.02 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.


Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc (NASDAQ:SLDB) announced its earnings results on Wednesday, August, 14th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05. View Solid Biosciences' Earnings History.

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Solid Biosciences.

What price target have analysts set for SLDB?

7 Wall Street analysts have issued 1-year price objectives for Solid Biosciences' shares. Their forecasts range from $2.00 to $22.00. On average, they expect Solid Biosciences' share price to reach $9.83 in the next twelve months. This suggests a possible upside of 139.3% from the stock's current price. View Analyst Price Targets for Solid Biosciences.

What is the consensus analysts' recommendation for Solid Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 2 sell ratings, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences.

Has Solid Biosciences been receiving favorable news coverage?

Media coverage about SLDB stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Solid Biosciences earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Solid Biosciences.

Are investors shorting Solid Biosciences?

Solid Biosciences saw a increase in short interest in November. As of November 29th, there was short interest totalling 3,630,000 shares, an increase of 16.3% from the November 14th total of 3,120,000 shares. Based on an average daily trading volume, of 783,100 shares, the days-to-cover ratio is presently 4.6 days. Currently, 12.0% of the shares of the stock are short sold. View Solid Biosciences' Current Options Chain.

Who are some of Solid Biosciences' key competitors?

What other stocks do shareholders of Solid Biosciences own?

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the folowing people:
  • Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)
  • Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)
  • Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)
  • Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)
  • Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48)

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.72%), State Street Corp (0.65%), Matisse Capital (0.15%), California State Teachers Retirement System (0.07%) and Rhumbline Advisers (0.05%). Company insiders that own Solid Biosciences stock include Boxer Capital, Llc, Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Life Sciences Maste Perceptive, Matthew Bennett Arnold and Pedro Alvaro Amorrortu. View Institutional Ownership Trends for Solid Biosciences.

Which major investors are buying Solid Biosciences stock?

SLDB stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, California State Teachers Retirement System, Rhumbline Advisers and Matisse Capital. View Insider Buying and Selling for Solid Biosciences.

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $4.11.

How big of a company is Solid Biosciences?

Solid Biosciences has a market capitalization of $189.02 million. The company earns $-74,800,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe.View Additional Information About Solid Biosciences.

What is Solid Biosciences' official website?

The official website for Solid Biosciences is http://www.solidbio.com/.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.


MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel